UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 1 filers reported holding UNIQURE NV in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,733,535 | +377.3% | 258,351 | +715.1% | 0.00% | – |
| Q2 2023 | $363,213 | -75.8% | 31,694 | -57.5% | 0.00% | -100.0% |
| Q1 2023 | $1,503,048 | +93.9% | 74,630 | +118.2% | 0.00% | +100.0% |
| Q4 2022 | $775,201 | -99.9% | 34,195 | -57.5% | 0.00% | -50.0% |
| Q3 2022 | $1,510,180,000 | +1925.5% | 80,500 | +1912.5% | 0.00% | – |
| Q2 2022 | $74,560,000 | -42.1% | 4,000 | -43.9% | 0.00% | – |
| Q1 2022 | $128,875,000 | -80.3% | 7,132 | -77.3% | 0.00% | -100.0% |
| Q4 2021 | $652,563,000 | -29.3% | 31,464 | +9.1% | 0.00% | 0.0% |
| Q3 2021 | $923,104,000 | +58.4% | 28,838 | +52.4% | 0.00% | 0.0% |
| Q2 2021 | $582,921,000 | +232.9% | 18,926 | +264.2% | 0.00% | – |
| Q1 2021 | $175,087,000 | -9.8% | 5,197 | -1.4% | 0.00% | – |
| Q3 2020 | $194,168,000 | -18.3% | 5,272 | 0.0% | 0.00% | – |
| Q2 2020 | $237,556,000 | – | 5,272 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |